InvestWiser

Corline Biomedical AB

CLBIONasdaq StockholmHealthcareMarket value 374 m SEK
14.30SEK −0.3%
last day · Price as of 18 November 2026

The answer first

Does Corline Biomedical beat the market?

No, Corline Biomedical has not beaten the market over the last year.

Corline Biomedical−20.3%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 3% of Nordic stocks

    • Quality28
    • Value7
    • Trend16

    No. 184 of 195 in healthcare

Max for seven days

Follow Corline Biomedical with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Corline Biomedical

From today, at a price of 14.30 SEK. Write why you follow Corline Biomedical, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Corline Biomedical

Your first answer is free, no account needed.

Do you own Corline Biomedical, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Corline Biomedical and a few more. Free, no card.

Past year against the exchange and Super Stock
Corline Biomedical−27.8%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Corline Biomedical has fallen 20.3% over the past year, including dividends.
  • Overall, Corline Biomedical ranks better than 3% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 65.9%. The price is 47.7% below its peak now.

What do analysts think of Corline Biomedical?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

3

Quality, value and trend together. Better than 3% of Nordic stocks.

No. 184 of 195 in healthcare

Quality28
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 160 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.11
  • Return on equityProfit divided by equity−12.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value7
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 149 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity3.6
  • P/SPrice divided by sales28.8
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend16
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 135 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−20.3%
  • 6 months−21.2%
  • 9 months−4.0%
  • 12 months−20.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+2.1%
3 years, per year
+0.9%
5 years, per year
−0.5%
10 years, per year
+6.2%
Largest fall, 3 years
−65.9%
From a peak to the bottom
From the peak now
−47.7%
How far the price is from the peak
Volatility, 1 year
41.4%
How much the price swings over a year
Beta, 1 year
0.30
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Corline Biomedical

One fund we follow owns Corline Biomedical. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Corline Biomedical

Corline Biomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 14 employees.

Corline Biomedical AB (publ) develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.

See the full analysis of Corline Biomedical.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market